Less Ads, More Data, More Tools Register for FREE

Pin to quick picksHutchmed Share News (HCM)

Share Price Information for Hutchmed (HCM)

Share Price is delayed by 15 minutes
Get Live Data
170.50    5.75 (3.49%)
Bid:
168.00
Ask:
172.00
Spread: 4.00 (2.381%)
Market Cap: £1.47b
HCM Live PriceLast checked at - London Stock Exchange

Intraday Hutchmed Share Chart

Hutchmed News

LONDON BRIEFING: JD Sports backs outlook; Spirent accepts new offer
28 Mar 2024

LONDON BRIEFING: JD Sports backs outlook; Spirent accepts new offer

(Alliance News) - Stocks in London traded higher early on Thursday in the final trading day of a holiday-shortened week, despite some hawkish words fr...

Hutchmed begins registration stage for sovleplenib phase 2/3 trial
22 Mar 2024

Hutchmed begins registration stage for sovleplenib phase 2/3 trial

(Alliance News) - Hutchmed (China) Ltd on Friday said it initiated the registration stage of the phase 2/3 clinical trial for sovleplenib, its warm an...

EARNINGS: Hutchmed revenue surges, Craven House's loss widens
28 Feb 2024

EARNINGS: Hutchmed revenue surges, Craven House's loss widens

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Wednesday and not separately reported by Alliance News:

Hutchmed hails fruquintinib trial results for gastric cancer treatment
7 Feb 2024

Hutchmed hails fruquintinib trial results for gastric cancer treatment

(Alliance News) - Hutchmed (China) Ltd on Wednesday said phase three data for fruquintinib in combination with paclitaxel showed an improvement in ove...

Hutchmed says Inmagene exercises option to licence drug candidates
2 Feb 2024

Hutchmed says Inmagene exercises option to licence drug candidates

(Alliance News) - Hutchmed (China) Ltd on Friday said Inmagene Biopharmaceuticals Ltd has exercised options to licence two drug candidates as part of ...

Hutchmed partner Inmagene exercises options over two drug candidates
2 Feb 2024

Hutchmed partner Inmagene exercises options over two drug candidates

(Sharecast News) - Hutchmed China announced on Friday that Inmagene Biopharmaceuticals has exercised options to licence two drug candidates, IMG-007 a...

Hutchmed's 'Elunate' approved under new Hong Kong rules
30 Jan 2024

Hutchmed's 'Elunate' approved under new Hong Kong rules

(Sharecast News) - Hutchmed China announced the approval of its drug 'Elunate', or fruquintinib, by the Pharmacy and Poisons Board of Hong Kong on Tue...